CHENGDU, China, July 27, 2022 /PRNewswire/ — Shanghai-listed company HitGen Inc. (“HitGen”) announced today that it has entered into a research collaboration agreement with LoQus23 Therapeutics Ltd. (“LoQus23”), a private biotechnology company that discovers small molecule therapies that target aberrant DNA damage repair to treat Huntington’s disease and other triplet repeat diseases (TRDs). HitGen will apply its DNA-encoded library (DEL) technology platform to discover compounds that bind to certain targets of interest to LoQus23.
Triplet repeat diseases are genetic disorders that primarily affect the nervous system and are caused by abnormal repeated expansions of trinucleotides. Human genome-wide association studies of Huntington’s disease and other TRDs have demonstrated that clinical measures of disease, such as age at onset and rate of progression, are significantly altered. critically by genetic variants that increase the activity of the mismatch repair pathway. Aberrant activity of this pathway leads to further expansions of trinucleotide repeats in the DNA sequence. This, in turn, results in greater toxicity in neurons in vulnerable regions of the brain, thus accelerating the rate of neurodegeneration. Differentiated, Structure-Based Approach to LoQus23 Targets DNA Damage Repair Proteins with Small Molecule Drugs to Stop DNA Instability and Slow Neurodegeneration in Huntington’s Disease, Myotonic Dystrophy type 1 and other DRTs.
HitGen is a world leader in the development of LED technology and its applications for early stage small molecule drug discovery. To explore therapies for challenging TRDs, LoQus23 will provide novel targets, and HitGen will screen its vast LEDs of over 1.2 trillion small molecules against these targets.
“LoQus23 is a highly innovative company with deep expertise in the pursuit of genetically validated targets for the treatment of triplet-repeat diseases. We look forward to working with LoQus23 to identify novel small molecule starting points from libraries encoded by We will work closely with LoQus23 scientists to generate new lead compounds for their research programs to address unmet medical needs associated with repairing aberrant DNA damage and improving life patients with devastating genetic diseases,” said Dr. Jin LiChairman of the Board and CEO of HitGen.
“HitGen is a global leader in DNA-encoded libraries and we look forward to working with their scientists to discover small molecules for novel DNA damage repair targets to expand LoQus23’s pipeline of innovative projects,” said dr. David Reynoldsco-founder and managing director of LoQus23.
HitGen has built four core technology platforms including DNA-Encoded Library (DEL), Molecular Fragment and Structure Design (FBDD/SBDD), Synthetic Therapeutic Oligonucleotide (STO), and Targeted Protein Degradation (TPD) ). HitGen’s LED technology platform, centered on the design, synthesis and interrogation of thousands of LEDs that collectively comprise more than 1.2 trillion drug-like small molecules, is also capable of providing services and products , including LED screening, a custom LED library, OpenDEL®etc Over the past few years, HitGen has worked with its partners to use the DEL platform to generate nearly 500 new licensed chemical structures for their research projects.